We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current 0JW9 market cap is 22.32M. The company's latest EPS is USD -4.7783 and P/E is -0.64.
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 4.92M | 28.91M | 25.54M | 40.7M | 48.82M |
| Operating Income | -46.25M | -24.54M | -69.69M | -75.48M | -36.76M |
| Net Income | -16.82M | -46.02M | -50.58M | -54.45M | -31.84M |
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 82.66M | 209.73M | 174.1M | 177.84M | 120.81M |
| Total Liabilities | 34.73M | 131.51M | 132.74M | 125.43M | 96.19M |
| Total Equity | 47.93M | 78.22M | 41.36M | 52.41M | 24.62M |
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -29.42M | 34.26M | -31.96M | -48.75M | -52.48M |
| Investing | 24.32M | -106.29M | 24.71M | 6.89M | 53.69M |
| Financing | 1.39M | 74.78M | 3.47M | 49.05M | -40k |
| Market Cap | 22.32M |
| Price to Earnings Ratio | -0.64 |
| Price to Sales Ratio | 0.42 |
| Price to Cash Ratio | 1.21 |
| Price to Book Ratio | 0.83 |
| Dividend Yield | - |
| Shares Outstanding | 6.66M |
| Average Volume (1 week) | 94 |
| Average Volume (1 Month) | 285 |
| 52 Week Change | 0.00% |
| 52 Week High | 3.35 |
| 52 Week Low | 3.35 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Mei Pharma Inc |
| Address |
1209 orange st wilmington, delaware 19801 |
| Website | https://www.meipharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
